New lung cancer drug shows promise in japanese study
NCT ID NCT04155541
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety and effectiveness of Vizimpro (dacomitinib) in 40 Japanese patients with EGFR-mutated non-small cell lung cancer that could not be surgically removed or had returned. Researchers tracked side effects, especially interstitial lung disease, and measured how well the drug shrank tumors. The study is now complete, and results will help doctors understand how Vizimpro works in real-world Japanese medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dacomitinib (Vizimpro)
What this could lead to
If results are positive, this could confirm that Vizimpro is a safe and effective option for treating EGFR-mutated lung cancer in Japanese patients.
What could go wrong
This was a small, single-country study with only 40 patients, so findings may not apply to broader populations. Side effects like interstitial lung disease are a known risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATION-POSITIVE INOPERABLE OR RECCRENT NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan